{
    "nctId": "NCT03057600",
    "briefTitle": "Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)",
    "officialTitle": "A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry",
    "overallStatus": "COMPLETED",
    "conditions": "Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 52,
    "primaryOutcomeMeasure": "Overall Response Rate (ORR)",
    "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Meets criteria for 1 of the 4 defined study cohorts\n* TNBC, defined as estrogen receptor (ER) and progesterone receptor (PR) negative (\\< 1% by immunohistochemistry) and human epidermal growth factor receptor 2 (HER2)-negative (immunohistochemistry 0 to 1+ or fluorescence in situ hybridization \\[FISH\\] negative)\n* Metastatic disease or locally-advanced disease not amenable to curative intent treatment\n* Adequate hepatic, renal, cardiac, and hematologic function\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Recovery to baseline or \u2264 Grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version.4.0\n\nKey Exclusion Criteria:\n\n* Known brain metastases or central nervous system (CNS) cancer unless adequately treated with radiotherapy and/or surgery and stable for \u2265 2 mo\n* Unable to receive oral medications\n* Known hypersensitivity to Cremophor\u00ae-based agents\n* Major surgery within 28 days of Cycle 1 Day 1",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}